1448186-49-9Relevant articles and documents
Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
-
Paragraph 0289; 0290; 0293, (2014/12/09)
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α
Buckley, Dennis L.,Gustafson, Jeffrey L.,Van-Molle, Inge,Roth, Anke G.,Tae, Hyun Seop,Gareiss, Peter C.,Jorgensen, William L.,Ciulli, Alessio,Crews, Craig M.
supporting information, p. 11463 - 11467 (2013/01/15)
By design: Novel small-molecule inhibitors of the interaction between the von Hippel-Lindau ligase (VHL) and its molecular target HIF1α, a transcription factor involved in oxygen sensing, have been developed and studied. The most potent inhibitor binds with an IC50 value of 0.9-μM and is thus the first sub-micromolar inhibitor of the VHL-HIF1α interaction. Copyright